Want to see BSEM full AI Analyst Report?
BSEM Stock Chart & Stats
$4.83
$0.88(5.85%)
At close: 4:00 PM EST
$4.83
$0.88(5.85%)
Day’s Range― - ―
52-Week Range$3.09 - $12.65
Previous CloseN/A
Volume47.30K
Average Volume (3M)70.05K
Market Cap
$52.94M
Enterprise Value$56.07M
Total Cash (Recent Filing)$13.70M
Total Debt (Recent Filing)$3.28M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 25, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding16,338,436
10 Day Avg. Volume60,312
30 Day Avg. Volume70,048
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue-2.96
Enterprise Value/Gross Profit-2.31
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$7.00Price Target Upside44.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$45.84M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsThe ~95% gross margin in 2024 indicates very strong unit economics for placental allograft products, implying durable pricing power and low incremental costs. Structurally high gross margins provide a lasting cushion to absorb SG&A and support recovery in profitability if revenue stabilizes.
Positive Cash GenerationMeaningful operating and free cash flow in 2024, and continued positive cash flow in 2025 despite declines, shows the business can generate internal liquidity. This durable cash generation reduces near-term financing dependence and supports ongoing commercialization and product development during cyclicality.
Modest Financial LeverageLow debt relative to equity in recent periods lowers refinancing and interest-rate vulnerability, giving management structural flexibility. Modest leverage supports the ability to invest in sales, partnerships, or R&D without immediate solvency pressure, improving resilience across 2-6 month horizons.
Bears Say
Severe Revenue DeclineA near-80% revenue collapse in 2025 materially weakens the company's underlying business stability and scale economics. Such a structural drop reduces operating leverage, makes fixed-cost absorption harder, and impairs the predictability of cash generation and commercial momentum over the medium term.
Return To Net LossesThe swing from 2024 profitability to a -13.9% net margin in 2025 highlights volatile earnings quality. Persistent or recurrent losses can force external financing, dilute shareholders, and constrain investment in commercial execution and product innovation, undermining longer-term growth prospects.
Historical Balance-Sheet InstabilityPrior periods of negative equity indicate past financial distress and likely reliance on dilutive financings. Even with recent modest leverage, this history raises the structural risk of future dilution or financing strain if revenue or margins slip again, complicating long-term capital planning.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $3.09 and its highest was $12.65 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $52.94M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s upcoming earnings report date is Aug 25, 2026 which is in 53 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on May 14, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.24.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Undervalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate is -0.5.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 16,338,436 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -14.167%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (44.93% Upside)
$7.00 (44.93% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.49%
12-Months-Change
Fundamentals
Return on Equity
-47.03%
Trailing 12-Months
Asset Growth
-63.11%
Trailing 12-Months
Company Description
BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BSEM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call communicated meaningful strategic positives — a transformational acquisition expanding addressable markets, strong clinical data (DFU RCT), product and commercial expansion, and a clear path to materially higher manufacturing margins after tech transfer. However, these longer-term strengths are offset by significant near-term financial headwinds: steep year-over-year revenue declines, a sizable one-time $8.8M allowance tied to distributor collections, higher operating expenses, lower blended margins during a 12-month contract manufacturing period, reduced post-close cash (~$16M) and expected cash consumption through much of 2026. Management has articulated a credible integration and commercialization plan, but near-term liquidity and execution risks temper the outlook.View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
$7.00
▲(44.93% Upside)
Technical Analysis
Crescent Biopharma
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Innate Pharma
―